NCT05566223 2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2 Withdrawn
Clinical Trials
6 trialsNCT03098355 2024-03-18
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT04389229 2020-12-16
OVSTAR
Immetacyte Ltd
Phase 1/2 Withdrawn
NCT03111901 2019-07-12
UVA-AM-002
University of Virginia
Phase 1/2 Withdrawn
NCT03297463 2018-08-01
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT01409187 2012-01-26
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn